In this article, we discuss 13 best pharma dividend stocks to buy in 2024. You can skip our detailed analysis of the pharma sector and its performance, and go directly to read 5 Best Pharma Dividend Stocks To Buy in 2024. Within the healthcare industry in the US, the pharmaceutical sector has experienced significant transformations […]
GSK said on Monday a new formulation of its HIV prevention and treatment drug could potentially be administered at least every four months, an improvement from the previous requirement of dosing every two months. Data on the ultra-long-acting cabotegravir was presented at the Conference on Retroviruses and Opportunistic Infections by GSK's HIV-focused unit, ViiV Healthcare, which plans to conduct large-scale clinical trials later this year. The company has shifted its HIV focus to long-acting treatments and prevention therapies, amid a series of upcoming patent expiries, litigations and declining revenue from current bestsellers.
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.